SCHEMBL4897584

SCHEMBL4897584

Cc1ccc(Cn2c(-c3cccc(-c4cccc(C(N)=O)c4)c3)cc(C(F)(F)F)c(C#N)c2=O)c(C)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 4/20 0.45
NR1H3 Q13133 4/20 0.45
RXRA P19793 3/20 0.45
ERN1 O75460 1/20 0.37
TNKS O95271 3/20 0.36
TNKS2 Q9H2K2 3/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
AKR1C3 P42330 1/20 0.35
AKR1C2 P52895 1/20 0.35
ALDH1A1 P00352 5/20 0.35
KDM4E B2RXH2 3/20 0.35
LMNA P02545 2/20 0.35
DHODH Q02127 2/20 0.34
AR P10275 1/20 0.34
GLA P06280 1/20 0.34
GAA P10253 1/20 0.34
HPGD P15428 1/20 0.34
ATM Q13315 1/20 0.34
MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4906328 0.94 NR1H2 (0.46) NR1H2NR1H3RXRATNKSTNKS2
SCHEMBL4905525 0.92 NR1H2 (0.46) NR1H2NR1H3RXRATNKSTNKS2
SCHEMBL4905674 0.90 NR1H2 (0.45) NR1H2NR1H3RXRATNKSTNKS2
SCHEMBL4906577 0.90 RXRA (0.44) NR1H2NR1H3RXRAERN1TNKS
SCHEMBL4902385 0.90 RXRA (0.44) NR1H2NR1H3RXRATNKSTNKS2
SCHEMBL4901910 0.89 RXRA (0.43) NR1H2NR1H3RXRA
SCHEMBL4907807 0.89 NR1H2 (0.47) NR1H2NR1H3RXRATNKSTNKS2
SCHEMBL4897697 0.88 NR1H2 (0.47) NR1H2NR1H3RXRATNKSTNKS2
SCHEMBL4901856 0.88 NR1H2 (0.47) NR1H2NR1H3RXRATNKSTNKS2
SCHEMBL2264167 0.87 NR1H2 (0.51) NR1H2NR1H3RXRATNKSTNKS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080119488-A1 Modulators Of Nuclear Receptors EXELIXIS, INC. (US) 2008-05-22 US claimed
US-20080119488-A1 Modulators Of Nuclear Receptors EXELIXIS, INC. (US) 2008-05-22 US disclosed
US-20080119488-A1 Modulators Of Nuclear Receptors EXELIXIS, INC. (US) 2008-05-22 US disclosed
US-20080119488-A1 Modulators Of Nuclear Receptors EXELIXIS, INC. (US) 2008-05-22 US disclosed
EP-1773337-A2 MODULATORS OF NUCLEAR RECEPTORS Exelixis, Inc. (US) 2007-04-18 EP disclosed
WO-2006025979-A9 MODULATORS OF NUCLEAR RECEPTORS EXELIXIS INC (US) 2006-04-20 WO disclosed
WO-2006025979-A2 MODULATORS OF NUCLEAR RECEPTORS EXELIXIS, INC. (US) 2006-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119488-A1 Modulators Of Nuclear Receptors NR1H2, NR0B1, NR1H3 NR1H2 1/4885NR1H3 3/4885RXRA 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.